Skip to main content
. 2013 Feb 22;6:31–39. doi: 10.2147/JAA.S39496

Table 3.

Incidence of adverse events is ≥2% as reported during the study by treatment group

Placebo (N=122) Rupatadine (N=119) Desloratadine (N=118) P-value (Chi-square test)
Patients reported AEs (%) 44 (36.1) 47 (39.5) 44 (37.3) NS
Drug-related AEs (%) 12 (9.8) 16 (13.4) 19 (16.1) NS
  Diarrhea 0 (-) 1 (0.8) 3 (2.5) NS
  Headache 1 (0.8) 2 (1.7) 5 (4.2) NS
  Somnolence 0 (-) 10 (8.4) 7 (5.9) NS
  Pharyngolaryngeal pain 3 (2.5) 0 (-) 2 (1.7) NS
Withdrawals due to AEs 0 0 0
Serious AEs 1 0 0